You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Tamoxifen added to lumpectomy and radiation therapy reduced breast cancer events in ductal carcinoma in situ

https://doi.org/10.1136/ebm.5.2.57

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    (1999) Lancet 353, 1993. Fisher B, Dignam J, Wolmark N, et al.. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial.. Jun 12;. :. –2000.
    OpenUrlCrossRefPubMedWeb of Science

    
 
 QUESTION: In women with non-invasive ductal carcinoma in situ (DCIS), does adding tamoxifen to lumpectomy and radiation therapy (RT) prevent cancer in ipsilateral and contralateral breasts?

    Design

    Randomised {allocation concealed*},† blinded {clinicians, patients, outcome assessors, and statisticians*},† placebo controlled trial with median 74 month follow up.

    Setting

    57 centres in the United States and Canada.

    Patients

    1804 women who had lumpectomy for DCIS, including those with or without lobular carcinoma in situ, and who were expected to live ≥10 years. 16% had positive resection margins. Women with previously diagnosed cancer other than in situ carcinoma of the cervix or basal cell or squamous cell carcinoma of the skin were excluded. Follow up was 99.7%.

    Intervention

    Lumpectomy and RT (50 Gy) began …

    View Full Text

    Footnotes

    • Sources of funding: National Institutes of Health; Department of Health and Human Services.

    • For correspondence: Prof B Fisher, National Surgical Adjuvant Breast and Bowel Project (NSABP), 4 Allegheny Center, Suite 602, Pittsburgh, PA 15212-5234, USA. Fax +1 412 330 4411.

    • ↵* See glossary.

    • ↵† Information provided by author.